Daiichi Sankyo gets $75M milestone from AstraZeneca after EU approves Enhertu for adjuvant HER2-positive early breast cancer

Daiichi Sankyo received a $75 million milestone payment from AstraZeneca after the EU approved Enhertu for adjuvant HER2-positive early breast cancer. The DESTINY-Breast05 trial showed a 53% lower recurrence or death risk versus T-DM1.

Detected & updated continuously · Source: Nebula